U.S. Women’s Health Market Size, Share & Trends Analysis Report By Application (Hormonal Infertility, Contraceptives, Postmenopausal Osteoporosis), By Age, By Drug, By Distribution Channel, And Segment- Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The U.S. women’s health market size was estimated at USD 21.6 billion in 2022 and is expected to surpass around USD 32.19 billion by 2032 and poised to grow at a compound annual growth rate (CAGR) of 4.07% during the forecast period 2023 to 2032.

Key Takeaways:

• The Prolia segment held the largest market share of 15.87% in 2022 and is anticipated to grow at the fastest CAGR over the forecast period.
• The Minastrin 24 Fe segment is expected to showcase a lucrative CAGR over the forecast period.
• The contraceptive segment held the largest market share of 36.51% in 2022
• The endometriosis & uterine fibroids segment is expected to showcase the fastest CAGR over the projected period.
• The others segment including women aged less than 50 years held the largest market share of 59.89% in 2022
• The 50 years and above segment is expected to showcase a significant CAGR over the forecast period.
• The hospital pharmacy segment led the U.S. women’s health market with the largest revenue share of 47.88% in 2022.
• The online pharmacy segment is estimated to showcase the fastest CAGR over the forecast period.

U.S. Women’s Health Market Report Scope

The rising prevalence of target diseases is a key driver for the growth of the market. With aging and the increasing prevalence of obesity, the prevalence of osteoarthritis is anticipated to grow. Some of the major factors responsible for hormonal imbalance in women include changes in dietary habits, stress, and consumption of alcohol, which can cause fertility issues. Ovulation problems, polycystic ovarian syndrome (PCOS), and endometriosis are major factors responsible for infertility.

The rise in public funding for family planning services is further driving the market growth. In the U.S., approximately 45% of pregnancies are estimated to be unwanted every year. Despite advancements in contraceptive technology and increased R&D spending on contraceptives, the rate of unplanned pregnancies in the U.S. has remained unchanged for decades. This has increased the economic burden on low-income families that do not have easy access to modern and more effective methods of contraception. Hence, federal & state governments are actively working toward improving family planning services and access to modern contraceptives. For instance, in 2019, the U.S. government provided USD 608 million in funding to UNFPA for family planning & reproductive health development.

Moreover, child marriages are most common in underdeveloped and developing economies, often leading to early and unplanned pregnancies. There is a lack of awareness about contraceptives, which amplifies the severity of the problem. According to UNICEF, child marriages decreased by 15% in the past decade. However, the number has not decreased over the years in the U.S. because laws in certain U.S. states allow marriages before 18 years. However, efforts to address child marriage and its impact on women’s health are being undertaken in the country, which involve advocating for policy changes, promoting girls' education, raising awareness about the negative consequences of child marriage, and providing support services for affected girls and women.

Furthermore, key players involved in developing and formulating various therapeutics are focusing on collaborations and partnerships to develop novel drugs and maintain their competitive position in the market. For instance, in October 2022, Solera Health announced the launch of first-of-its-kind digital point solutions for women's Health networks to address women’s health issues needs. Moreover, in November 2022, Sebela Pharmaceuticals announced the launch of a new division fully dedicated to women’s health.

Drug Insights

The Prolia segment held the largest market share of 15.87% in 2022 and is anticipated to grow at the fastest CAGR over the forecast period. Prolia is a medication used in the field of women's health for the treatment and prevention of osteoporosis in postmenopausal women. The generic name for Prolia is denosumab. Prolia is a monoclonal antibody that works by inhibiting a protein called RANK ligand, which plays a key role in the process of bone resorption. By blocking the RANK ligand, Prolia helps reduce bone loss, increase bone density, and decrease the risk of fractures in postmenopausal women with osteoporosis.It is typically administered as an injection every six months by a healthcare professional.

The Minastrin 24 Fe segment is expected to showcase a lucrative CAGR over the forecast period. Minastrin 24 Fe is a brand name for a combination birth control pill used in women's health. It contains two hormones, norethindrone acetate (a progestin) and ethinyl estradiol (an estrogen), and is primarily prescribed as an oral contraceptive to prevent pregnancy. Minastrin 24 Fe works by preventing ovulation (the release of an egg from the ovary), thickening the cervical mucus to inhibit sperm movement, and affecting the lining of the uterus to make it less receptive to implantation.

Application Insights

The contraceptive segment held the largest market share of 36.51% in 2022 due to rapid technological advancements in contraception and an increase in awareness about family planning. Favorable government regulations and increasing awareness about different contraceptive methods in the U.S. are likely to drive the adoption of contraceptives and contribute to the market’s growth. For instance, U.S. Federal law mandates that all female-controlled contraceptive methods are covered without out-of-pocket patient costs. Counseling and related services for female contraception are also mandatorily covered. Moreover, key players constantly focus on product launches to meet the rising demand for contraceptives. For instance, in July 2022, Perrigo Company plc announced that it had submitted an application for the first-ever OTC birth control pill to the U.S. FDA.

The endometriosis & uterine fibroids segment is expected to showcase the fastest CAGR over the projected period. The growth can be attributed to several factors, such as the high prevalence of uterine fibroids among women in the U.S., an increasing preference for less invasive procedures by patients, and the high adoption of advanced technologies. Uterine fibroids are characterized by symptoms such as extreme menstrual flow, infertility, pelvic pain, and frequent urination. They are benign tumors that develop in the smooth muscle cells of the uterus.Furthermore, the market is expected to grow due to the increasing preference for minimally invasive and noninvasive procedures for fibroid treatment.

Age Insights

The others segment including women aged less than 50 years held the largest market share of 59.89% in 2022 and is anticipated to grow the fastest during the forecast period. The growth of the segment is attributed to the rising prevalence of women’s health conditions in the age group. Women below 50 are mainly of reproductive age and women’s health concerns in this age group are more likely associated with fertility, such as endometriosis, hormonal infertility, and PCOS. According to World Bank, in 2020, globally, around 64.8% of women are aged between 15 and 49, which is around 1.9 billion out of 3.8 billion of the total women population.

The 50 years and above segment is expected to showcase a significant CAGR over the forecast period. Women aged 50 and above form the core demographic that undergoes menopause, and hence, demand & adoption of postmenopausal products are high in this segment. According to UN 2020 global estimates, 958 million women were aged 50 and above. By 2050, this demographic is expected to reach 1.65 billion. NAMS stated that every day an estimated 6,000 women in the U.S. reach menopause, which totals more than 2 million women undergoing menopause per year.An increase in life expectancy has led to a rise in the menopausal population worldwide. The post-menopause period is expected to account for one-third of women’s lives.

Distribution Channel Insights

The hospital pharmacy segment led the U.S. women’s health market with the largest revenue share of 47.88% in 2022. It is expected to maintain a dominant share throughout the forecast period. Hospital pharmacies give better access to women’s health products for both inpatient and outpatient. Some patients admitted to hospitals for complicated surgeries also need to take medications, including estrogen, progesterone, and other hormone treatment combination therapies. Additionally, for some eye-related disorders, these are effective for outpatients. Hospital stay duration, overall healthcare expenses, level of treatment, and emergency care are all positively impacted by the presence of these facilities.

The online pharmacy segment is estimated to showcase the fastest CAGR over the forecast period. The growth can be attributed to greater internet accessibility and more knowledge of over-the-counter medicines, online pharmacies are being rapidly adopted in the U.S. Additionally, the COVID-19 pandemic favorably impacted the market, driving it at an exponential pace due to constraints on migration. However, online pharmacies are seeing a fall in sales as the situation has generally de-escalated. E-prescriptions are another factor in this market's expansion, and as this trend gains traction, it may help the situation for online pharmacies.

Key Companies & Market Share Insights

The key players operating in women’s health therapeutics continue to concentrate on improving existing technologies and introducing new therapeutics that help improve patient outcomes and considerably increase healthcare efficiency and effectiveness. For Instance, in April 2023, Ferring B.V. collaborated with BioInnovation Institute Foundation (BII) to accelerate innovation in women's health. Some prominent players in the U.S. women’s health market include:

• AbbVie Inc.
• Bayer AG
• Merck & Co., Inc. (ORGANON)
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd.
• Agile Therapeutics, Inc.
• Amgen, Inc.
• Apothecus Pharmaceutical Corp.
• Lilly (Eli Lilly)
• Ferring B.V.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the U.S. Women’s Health market.

By Drug 

• ACTONEL
• YAZ,Yasmin,Yasminelle
• FORTEO
• Minastrin 24 Fe
• Mirena
• NuvaRing
• ORTHO TRI-CY LO
• Premarin
• Prolia
• Reclast/Aclasta
• XGEVA
• Zometa
• Others

By Application 

• Hormonal Infertility
• Contraceptives
• Postmenopausal Osteoporosis
• Endometriosis & Uterine Fibroids
• Menopause
• Polycystic Ovary Syndrome (PCOS)

By Age 

• 50 years and above
  • Postmenopausal Osteoporosis
  • Endometriosis & Uterine Fibroids
  • Menopause
  • Others
• Others

By Distribution Channel 

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy